Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-10-Speech-1-246-000"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.20120910.29.1-246-000"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spokenAs | |
lpv:translated text |
"Madam President, the revision of the rules regulating pharmacovigilance at EU level is a necessary and welcome step. The current system needs to be tightened to ensure greater safety and close existing loopholes. It is of paramount importance that the information provided on medicine labels is clear and helpful and worded in a way that everyone can understand. This will enable both patients and health care professionals to act accordingly. At the same time, the side effects of medicinal products must be monitored much more closely. This will put an end to cases like the one involving Mediator, the medicine from France which nearly all my colleagues have mentioned.
Transparency with regard to the safety of medicines is crucial to protecting public health. I should point out that the benefits gained by patients from a medicine should always outweigh any possible harm caused by the occurrence of side effects."@en1
|
lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples